Christopher Astle - 24 Feb 2022 Form 3 Insider Report for Zymeworks Inc.

Role
SVP & Chief Financial Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
24 Feb 2022
Net transactions value
$0
Form type
3
Filing time
04 Mar 2022, 20:20:57 UTC
Next filing
11 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ZYME Common Shares 670 24 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZYME Stock Option (Right to Buy) 24 Feb 2022 Common Shares 17,250 $29.81 Direct F1, F2
holding ZYME Restricted Stock Unit 24 Feb 2022 Common Shares 3,100 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% on May 17, 2022 (the first anniversary of grant date) and (ii) remainder in 36 equal monthly installments on last day of each month following first anniversary of grant date.
F2 The exercise price of the stock option was converted from CAD36.01 using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F3 The restricted stock units vest in two equal annual installments beginning on December 10, 2022.
F4 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney